Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer

Breast Cancer Research and Treatment

Volumn 94, Issue 3, 2005, Pages 205-211

  Mohsin, Syed K ^a,e   Allred, D Craig ^a   Osborne, C Kent ^a   Cruz, Anatolio ^b   Otto, Pamela ^b   Chew, Helen ^c   Clark, Gary M ^d   Elledge, Richard M ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OSI PHARMACEUTICALS INC   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Estrogen receptor; Molecular markers; Prevention; Tamoxifen

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN; PROTEIN BCL 2; TAMOXIFEN;

ADULT; ARTICLE; BREAST; BREAST CANCER; BREAST HYPERPLASIA; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; MORPHOLOGY; NEEDLE BIOPSY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOPREVENTION; ENDPOINT DETERMINATION; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MIDDLE AGED; PHENOTYPE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 27944486767     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-4896-1     Document Type: Article

References (34)

1. The Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998
2. Fisher B, Costantino J, Wickerham DL, Redmond C, Kavanah MT, Cronin WM, Vogel V, Robidoux A, Dimitrov NV, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388, 1998
3. van der Hage JA, van de Velde C, Julien J-P, Tubiana-Hulin M, Vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol 19: 4224-4237, 2001
4. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB, Jr., Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493, 1997
5. ATAC, Trialist's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. The Lancet 359: 2131-2139, 2002
6. Dowsett, M., Smith, I.E., Trialists, I. Greater Ki67 response after 2 weeks neoadjuvant treatment with anastrozole (A) than with tamoxifen (T) or anastrozole plus tamoxifen (C) in the IMPACT trial: a potential predictor of relapse-free survival. Breast Cancer Res Treatment 82: 56, 2003
7. DuPont WD, Page DL: Risk factors for breast cancer in women with proliferative breast disease. New Engl J Med 312: 146-151, 1985
8. London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease, the risk of breast cancer. JAMA: The J Am Med Assoc 267: 941-944, 1992
9. Dupont WD, Parl FF, Hartmann WH, Brinton LA, Winfield AC, Worrell JA, Schuyler PA, Plummer WD: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71: 1258-1265, 1993
10. Pike MC, Spicer DV, Dahmoushm L, Press M: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15: 17-35, 1993
11. Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger T, Martini PGV, Montano M, Sun J, Weis K, Katzenellenbogen JA: Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. Steroid Biochem Mol Biol 74: 279-285, 2000
12. Allred DC, Mohsin S: Biological features of premalignant disease in the human breast. J Mammary Gland Biol Neoplasia 5: 351-364, 2000
13. Giri D, Dundas S, Nottingham J, Underwood J: Oestrogen receptors in benign epithelial lesions and intraduct carcinomas of the breast: an immunohistological study. Histopathology 15: 575-584, 1989
14. Elledge RM, Clark GM, Fuqua SA W, Yu Y-Y, Allred DC: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock Protein 70 in breast cancer. Cancer Res 54: 3752-3757, 1994
15. London S, Connolly J, Schnitt SJ, Colditz GA: A prospective study of benign breast disease, the risk of breast cancer. JAMA: The J Am Med Assoc 267: 941-944, 1992
16. Foote FW, Stewart FW: Comparative studies of cancerous versus non-cancerous breasts. Ann Surg 121: 197, 1945
17. Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR: Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 60: 2751-60, 1987
18. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC: Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 90: 697-703, 1998
19. Walker KJ, Price-Thomas JM, Candish W, Nicholson RI: Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 64: 764-768, 1991
20. Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE, Jr., O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA, Browne D: Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10: 5403-5417, 2004
21. Jackman RJ, Nowels KW, Rodriguez-Soto J, Marzoni F, Finkelstein S, Shepard MJ: Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: False-negative and histologic underestimation rates after long-term follow-up. Radiology 210: 799-805, 1999
22. Dmytrasz K, Tartter PI, Mizrachy H, Chinitz L, Smith SR, Estabrook A: The Significance of Atypical Lobular Hyperplasia at Percutaneous Breast Biopsy. The Breast J 9: 10-12, 2001
23. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW, Johnson KA: A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8: 3105-3117, 2002
24. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, Mayo MS: Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst 92: 1217-1227, 2000
25. van t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536, 2002
26. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
27. Wilson L, Vlahou A, Gregory B, Perry RR, McGaughey D, Semmes O, Wright Jr, GL, Laronga C. A blood test for breast cancer detection. Breast Cancer Res Treatment 76: S-34, 2002
28. O'Shaughnessy JA, Ljung BM, Dooley WC, Chang J, Kuerer HM, Hung DT, Grant MD, Khan SA, Phillips RF, Duvall K, Euhus DM, King BL, Andersen BO, Troyan SL, Kim J, Veronesi U, Cazzaniga M: Ductal lavage and the clinical management of women at high risk for breast carcinoma: a commentary. Cancer 94: 292-298, 2002
29. Dooley WC: Ductal lavage, nipple aspiration, and ductoscopy for breast cancer diagnosis. Curr Oncol Rep 5: 63-5, 2003
30. Dooley WC, Spiegel A, Cox C, Henderson R, Richardson L, Zabora J: Ductoscopy: defining its role in the management of breast cancer. Breast J 10: 271-272, 2004
31. Mokbel K, Elkak AE: The evolving role of mammary ductoscopy. Curr Med Res Opin 18: 30-32, 2002
32. Yamamoto D, Tanaka K : A review of mammary ductoscopy in breast cancer. Breast J 10: 295-297, 2004
33. Sartorius OW, Smith HS, Morris P, Benedict D, Friesen L: Cytologic Evaluation of Breast Fluid in the detection of breast disease. J Natl Cancer Inst 59: 1073-1078, 1977
34. Wrensch M, Petrakis N, King E, Miike R, Mason L, Chew K, Lee M, Ernster VL, Hilton JF, Schweitzer R, Goodson WH, III, Hunt TK: Breast Cancer Incidence in Women with Abnormal Cytology in Nipple Aspirates of Breast Fluid. Am J Epidemiol 135: 130-140, 1992